Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240316 | 0.82 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL10665125 | 0.81 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL11537460 | 0.80 | MEN1 (0.63) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL13841479 | 0.79 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL9045499 | 0.79 | GAA (0.68) | RAB9ANPC1TP53LMNAPKM | |
| SCHEMBL4119504 | 0.79 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL9885823 | 0.78 | ALDH1A1 (0.67) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL6887530 | 0.78 | NLRP3 (0.67) | MAPTLMNAPKMKMT2AMEN1 | |
| SCHEMBL30440441 | 0.78 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL2190227 | 0.78 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | claimed |
| EP-2840081-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | Medicinal Bioconvergence Research Center (KR) | 2015-02-25 | — | — | EP | claimed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | claimed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| EP-2840081-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | Medicinal Bioconvergence Research Center (KR) | 2015-02-25 | — | — | EP | disclosed |
| CN-104379565-A | Novel aminopyridine derivatives for preventing or treating cancer | MEDICINAL BIOCONVERGENCE RES CT | 2015-02-25 | — | — | CN | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | DPYD, BRCA1, CYC1 | RAB9A 2499/4885NPC1 3555/4885SMN1; SMN2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.